dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs, Satsuma Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
NCT03901482: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Completed
3
1201
US
Dihydroergotamine, Dihydroergotamine Mesylate, Placebos, STS101 Placebo
Satsuma Pharmaceuticals, Inc.
Migraine, Migraine With Aura, Migraine Without Aura
07/20
08/20
SUMMIT, NCT04940390: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Completed
3
1591
US
Dihydroergotamine, Dihydroergotamine Mesylate, Placebo, STS101 Placebo
Satsuma Pharmaceuticals, Inc.
Migraine, Migraine With Aura, Migraine Without Aura
10/22
10/22
ASCEND, NCT04406649: A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

Completed
3
482
US
Dihydroergotamine, Dihydroergotamine Mesylate
Satsuma Pharmaceuticals, Inc.
Migraine, Migraine With Aura, Migraine Without Aura
01/23
01/23

Download Options